CN1698648A - 蒙脱石分散片及其制备工艺 - Google Patents
蒙脱石分散片及其制备工艺 Download PDFInfo
- Publication number
- CN1698648A CN1698648A CNA200410042539XA CN200410042539A CN1698648A CN 1698648 A CN1698648 A CN 1698648A CN A200410042539X A CNA200410042539X A CN A200410042539XA CN 200410042539 A CN200410042539 A CN 200410042539A CN 1698648 A CN1698648 A CN 1698648A
- Authority
- CN
- China
- Prior art keywords
- disintegrating agent
- dispersible tablet
- montmorillonitum
- described dispersible
- weight portion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 238000000034 method Methods 0.000 title claims description 16
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 title abstract 3
- 229910052901 montmorillonite Inorganic materials 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 41
- 239000007919 dispersible tablet Substances 0.000 claims description 35
- 229920002472 Starch Polymers 0.000 claims description 25
- 239000008107 starch Substances 0.000 claims description 24
- 235000019698 starch Nutrition 0.000 claims description 24
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 21
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 18
- 239000011734 sodium Substances 0.000 claims description 18
- 229910052708 sodium Inorganic materials 0.000 claims description 18
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 17
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 17
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 17
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 17
- QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 15
- 239000000945 filler Substances 0.000 claims description 14
- 238000005516 engineering process Methods 0.000 claims description 13
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 12
- 239000001117 sulphuric acid Substances 0.000 claims description 12
- 235000011149 sulphuric acid Nutrition 0.000 claims description 12
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 claims description 12
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 claims description 12
- 235000012141 vanillin Nutrition 0.000 claims description 12
- 108010011485 Aspartame Proteins 0.000 claims description 11
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 11
- 239000000605 aspartame Substances 0.000 claims description 11
- 235000010357 aspartame Nutrition 0.000 claims description 11
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 11
- 229960003438 aspartame Drugs 0.000 claims description 11
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 11
- 238000004132 cross linking Methods 0.000 claims description 11
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 11
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
- 239000008187 granular material Substances 0.000 claims description 10
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 claims description 9
- 241001279009 Strychnos toxifera Species 0.000 claims description 8
- 229960005453 strychnine Drugs 0.000 claims description 8
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 7
- 238000004090 dissolution Methods 0.000 claims description 6
- CBOQJANXLMLOSS-UHFFFAOYSA-N ethyl vanillin Chemical compound CCOC1=CC(C=O)=CC=C1O CBOQJANXLMLOSS-UHFFFAOYSA-N 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- 235000012239 silicon dioxide Nutrition 0.000 claims description 4
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 3
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims description 3
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 claims description 2
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 claims description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 229940073505 ethyl vanillin Drugs 0.000 claims description 2
- 229940085605 saccharin sodium Drugs 0.000 claims description 2
- 229940013618 stevioside Drugs 0.000 claims description 2
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 2
- 235000019202 steviosides Nutrition 0.000 claims description 2
- 229940117960 vanillin Drugs 0.000 claims description 2
- 239000002932 luster Substances 0.000 abstract description 2
- 239000004067 bulking agent Substances 0.000 abstract 1
- 239000007970 homogeneous dispersion Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 206010012735 Diarrhoea Diseases 0.000 description 11
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 10
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 10
- 238000001035 drying Methods 0.000 description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 208000019902 chronic diarrheal disease Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 208000007882 Gastritis Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 201000009840 acute diarrhea Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000000741 diarrhetic effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000004682 mucosal barrier function Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- VNIVZTFZIJTNDV-ZEYGOCRCSA-N (4ar,5as,8ar,13as,15as,15br)-4a,5,5a,7,8,13a,15,15a,15b,16-decahydro-2h-4,6-methanoindolo[3,2,1-ij]oxepino[2,3,4-de]pyrrolo[2,3-h]quinoline-14-one;phosphoric acid Chemical compound OP(O)(O)=O.O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 VNIVZTFZIJTNDV-ZEYGOCRCSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 235000019890 Amylum Nutrition 0.000 description 1
- 208000012639 Balance disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000019637 Infantile Diarrhea Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229910001051 Magnalium Inorganic materials 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- ALSPKRWQCLSJLV-UHFFFAOYSA-N azanium;acetic acid;acetate Chemical compound [NH4+].CC(O)=O.CC([O-])=O ALSPKRWQCLSJLV-UHFFFAOYSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- WUKWITHWXAAZEY-UHFFFAOYSA-L calcium difluoride Chemical compound [F-].[F-].[Ca+2] WUKWITHWXAAZEY-UHFFFAOYSA-L 0.000 description 1
- 229940087511 calcium disodium versenate Drugs 0.000 description 1
- 229910001634 calcium fluoride Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- -1 hydroxypropyl Chemical group 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000000689 peptic esophagitis Diseases 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229910052573 porcelain Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 229910021647 smectite Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 229940062854 strychnine phosphate Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- ORZHVTYKPFFVMG-UHFFFAOYSA-N xylenol orange Chemical compound OC(=O)CN(CC(O)=O)CC1=C(O)C(C)=CC(C2(C3=CC=CC=C3S(=O)(=O)O2)C=2C=C(CN(CC(O)=O)CC(O)=O)C(O)=C(C)C=2)=C1 ORZHVTYKPFFVMG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/12—Magnesium silicate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了蒙脱石分散片及其制备工艺，涉及蒙脱石的新药用制剂，其由蒙脱石、填充剂和崩解剂组成，具有质量稳定，崩解迅速且分散均匀，剂量易于掌握，运输携带方便，口味适宜，片面光滑，色泽一致。
Description
技术领域
本发明涉及蒙脱石的药物新制剂，具体涉及蒙脱石分散片及其制备工艺。
背景技术
蒙脱石作为一种高效的消化道粘膜保护剂和病毒、病菌及其毒素的吸附剂用于治疗各种急慢性腹泻已经在国内外被使用了很多年。
腹泻最直接的并发症是脱水，电解质平衡紊乱和营养吸收障碍，治疗时应注意补液，提倡适宜地继续饮食，但是单纯的补液不能治疗腹泻的病因，也不能明显缩短腹泻病程或减少腹泻的次数、腹泻量，因此还需要合理用药治疗。WHO对腹泻用药规定了六条标准：高效、可口服、可与ORS合用、不被肠道吸收、不影响肠道的吸收功能，尤其是葡萄糖和氨基酸的吸收功能，可抵御一系列肠道疾病。
蒙脱石具有消化道病原清除和粘膜保护作用，是一种安全，高效抗腹泻新药，符合WHO上述标准。AUGET等用蒙脱石治疗3073例腹泻患儿，其中急性2082例、迁延性991例，有效率为92.5％。HENDIER用蒙脱石联合或治疗36例婴儿腹泻，全部病例3天治愈而对照组则需要5天才能治愈。
目前，消化道疾病的治疗和临床用药都存在着一些问题，主要表现在单纯强调对抗致病病原体及攻击性因子的治疗方法。而在一定程度上忽视了维护消化道粘膜屏障及其在疾病治疗、转归和预后中的作用。蒙脱石不仅具有清楚病原体及其毒素的作用，对消化道粘膜屏障具有保护加强、修复作用、改善粘液质量、平衡正常菌群，促进上皮细胞再生和修复。
药理试验和临床结果表明，蒙脱石的药理作用是独特的层片结构，不均匀电荷分布和滑动粘塑性，可均匀连续覆盖再消化道表面，以静电和物化作用发挥疗效，对各种急慢性腹泻、反流性食管炎，慢性胃炎消化性溃疡肠易激综合症及炎症性肠病匀具有良好的疗效。而且对于某些临床上颇为棘手的病征，如应急性溃疡，大剂量放化疗引起的口腔炎和消化道并发症取得了显著的效果，丰富了临床治疗手段，是目前最理想的消化道粘膜保护剂。
蒙脱石安全性高、病人容易接受，对于婴幼儿、孕妇、老年人和肝肾功能不良者尤为适宜。
目前，市场上蒙脱石的药物剂型为散剂，这种剂型存在一定的不足，服用不方便剂量也不容易掌握，加水搅拌均匀口服，有沙砾感、土腥味，患者不易接受，特别是婴幼儿及青少年减量服用时，存在一定的困难。
发明内容
本发明提供一种新的蒙脱石分散片及其制备方法。
本发明蒙脱石分散片由蒙脱石、填充剂和崩解剂组成。
本发明蒙脱石分散片优选由100重量份的蒙脱石，3-20重量份的填充剂和1-8重量份的崩解剂组成；进一步优选为由100重量份的蒙脱石，10重量份的填充剂和3重量份的崩解剂组成。
本发明中，蒙脱石为各种可药用的蒙脱石，但优选采用符合国家药品标准的蒙脱石；
填充剂可采用各种水溶性填充剂或水不溶性填充剂，其中水溶性填充剂如乳糖、蔗糖、甘露醇、山梨醇等；水不溶性填充剂如，微晶纤维素、硫酸钙、磷酸氢钙、淀粉等；本发明优选采用水不溶性填充剂，进一步优选为微晶纤维素、羧甲基淀粉、淀粉中的一种、两种或两种以上组合。
本发明中，崩解剂可以采用各种可药用的常规崩解剂或溶胀性辅料，崩解剂如羧甲基淀粉钠，低取代羟丙基纤维素，交联聚乙烯吡咯烷酮，交联羧甲基纤维素钠，微晶纤维素，天然黏土硅胶铝镁等；溶胀性辅料如瓜尔胶，苍耳胶，藻酸盐，葡聚糖，可压性淀粉，预凝胶淀粉，多糖类及羧甲基纤维素钙，羟丙基甲基纤维素，羟丙基纤维素等亲水性高分子聚合物。
本发明中崩解剂优选为羧甲基淀粉钠、低取代羟丙基纤维素、交联羧甲基纤维素钠中的一种、两种或两种以上组合。
本发明崩解剂可以选择内加崩解剂或外加崩解剂或选择内外同时加入崩解剂；但优选采用内外同时加入崩解剂，其中内加崩解剂和外加崩解剂可以为不同的崩解剂也可以为同一种崩解剂。
本发明中内加崩解剂和外加崩解剂为羧甲基淀粉钠、低取代羟丙基纤维素、交联羧甲基纤维素钠中的一种、两种或两种以上组合。
本发明内加崩解剂和外加崩解剂的重量比为1∶1-4，进一步优选为内加崩解剂和外加崩解剂的重量比为1∶2。
为了使本发明获得更佳的口感，本发明还加入适量的矫味剂，矫味剂可以采用本领域常规使用的各种轿味剂，但优选为甜菊糖、糖精钠、阿斯巴甜、香草醛、乙基香草醛中的一种、两种或两种以上组合。
本发明蒙脱石分散片可以采用本领域常规的制备工艺进行制备，优选采用如下制备工艺：将矫味剂均匀后，用等容积递增法与填充剂、蒙脱石和内加崩解剂混均，制粒，再加入外加崩解剂混匀，压制成片即得。
本发明根据需要还可以加入其它的药用辅料，如适量助流剂，具体如1％微粉硅胶、硬脂酸镁、滑石粉、聚乙二醇、氢化植物油、十二烷基硫酸镁等，选用时应考虑其对分散片硬度、崩解度与溶出度的影响。
根据需要可以将本发明蒙脱石分散片制备成不同的规格，如：0.5g/片，1g/片，2g/片等。
本发明蒙脱石分散片优选采用1g/片规格的分散片。
本发明蒙脱石分散片含蒙脱石应为标示量的80.0％-95.0％；
在鉴别项下：本发明蒙脱石分散片应显硅酸盐，铝盐的阳性反应；
在检查项下：每片应吸附硫酸士的宁(C42H44NO4·H2SO4·5H2O)0.3～0.5g，含二氧化硅不得少于500mg，三氧化二铝不得少于100mg，其溶出度应为片重的70％以上。
本发明蒙脱石分散片的鉴别检查方法可以采用本领域常规的方法进行，但优选采用以下方法进行。
鉴别项中：
(1)分别取本品细粉和氟化钙各0.5g，置同一铂坩埚内，加浓硫酸1ml润湿，用已加水一滴的透明塑料板盖住坩埚，如必要可缓缓加热，在水滴表面有白色胶体生成。
(2)取本品细粉1.0g，置瓷蒸发皿中，加水10ml与硫酸5ml，加热至产生白烟，冷却，缓慢加水20ml，煮沸2-3分钟，滤过。滤液呈铝盐的鉴别反应(中国药典2000年版二部附录III)。
检查项中：
颗粒细度：取本品10片，加水50ml，振摇分散后强烈搅拌15分钟(转速不低于5000转/分)；将搅拌后的内容物傾入已用水润湿的45μm的药筛上，并用水冲洗药筛至澄清，将药筛上残留物用洗瓶转移至已恒重的坩埚中，缓缓炽灼至500-600℃，2小时，残留物不得过0.1g。
吸附力：取本品10片，研细，精密称取适量(约相当于蒙脱石0.2g)，置具塞锥形瓶中，精密加入磷酸盐缓冲液(pH6.8)10ml，振摇1小时，放置24小时，精密加入硫酸士宁溶液(取硫酸士的宁约2g，精密称定，置100ml量瓶中，加水适量，水浴中加热溶解，放冷至室温，加水稀释至刻度，摇匀，即得)10毫升，置37℃水浴中，振摇1小时，滤过，精密量取续滤液10ml，置250ml量瓶中，加磷酸盐缓冲液(pH6.8)稀释至刻度，摇匀，精密量取5ml，置50毫升量瓶中，加磷酸盐冲液(pH6.8)稀释至刻度，摇匀，照分光光度法(中国药典2000年版二部附录IV一)，在254nm的波长处测定吸收度；另取上述硫酸士的宁溶液适量制成每1毫升含20g的硫酸士的宁磷酸盐缓冲液(pH6.8)溶液，同法测定吸收度，按下式计算吸附力。
A1：硫酸士的宁对照溶液吸收度
A2：样品溶液吸收度
M1：硫酸士的宁重量
M2：称样量
M3：平均片重
D1：硫酸士的宁对照溶液稀释倍数
D2：样品溶液稀释倍数
G：规格量
每片应吸附硫酸士的宁(C42H44NO4·H2SO4·5H2O)0.3～0.5g。
二氧化硅：取本品10片，研细，精密称取适量(约相当于蒙脱石0.5g)，置铂坩埚中，加入0.5g碳酸钠和0.5g碳酸钾，搅匀，缓慢升温，在800℃下炽灼3小时，冷却，分次加入稀盐酸共50ml，搅拌使残渣完全溶解并转移到250ml烧杯，坩埚用少量水分次洗涤，洗液并入烧杯中，加热蒸去约1/2体积的溶液后，放冷，加入20毫升盐酸和1ml2％明胶溶液，于60～70℃水浴保温10分钟，时时搅拌，趁热过滤，并用热水洗涤容器，收集滤液和洗液备用；然后将滤纸和残渣移入已炽灼至恒重的坩埚中，在1100℃炽灼至恒重计算，即得，每片含二氧化硅不得少于500毫克。
三氧化二铝：取上述滤液和洗液，置250ml量瓶中，加水稀释至刻度，摇匀，精密移取75ml，氨试液中和至恰析出白色沉淀，再滴加稀盐酸至白色沉淀恰溶解，滤过，取滤液加醋酸-醋酸铵缓冲液(pH6.0)10ml，再加乙二胺四醋酸二钠滴定液(0.05mol/L)约25ml，煮沸5分钟，放冷至室温，加二甲酚橙指示液1ml，用锌滴定液(0.05mol/L)调至溶液恰变为红色，然后加氟化钠0.4g，煮沸2分钟，放冷后，用锌滴定液(0.05个摩尔/L)滴定至溶液由黄色转变为红色。每1ml锌滴定液(0.05mol/L)相当于2.549mg的Al2O3。每片含三氧化二铝不得少于100mg。
溶出度：取本品，照溶出度测定法测定，(中国药典2000年版附录XC第二法)以水900ml为溶剂，转速每分钟200转，至45分钟时，取100ml置105℃干燥至恒重的蒸发皿中，水浴蒸干，将蒸发皿于105℃干燥3小时，称重，计算，应为实际片重的70％以上。
本发明含量测定应符合以下标准：取本品10片，精密称定，研细，精密称取适量(约相当于蒙脱石0.2g)置已恒重的坩埚中，于1000±50℃炽灼至恒重，计算即得。
本发明分散片除溶出度外应符合中国药典2000年版2部附录I一片剂项下有关各项规定。
本发明者依据蒙脱石的性质，以本发明蒙脱石分散片质量、外观、吸附力、颗粒细度、分散均匀性作为检查项，做了加速6个月、长期室温留样观察12个月等实验，结果显示本发明质量非常稳定。
实验表明本发明蒙脱石分散片崩解迅速，可在1分钟内完全崩解，溶出速度快且分散均匀。
本发明蒙脱石分散片可用来治疗成人及儿童的急性、慢性腹泻、胃炎、食管炎、结肠炎、胃食管反流炎、肠易激综合症、肠道菌群失调。
本发明还可以用于胃、食道、十二指肠疾病引起的相关疼痛症状的辅助治疗。
本发明蒙脱石分散片为灰白色或类白色，味香甜，其中成人的服用方法为一次3片(1g/片)，每日三次；幼儿一次一片，每日三次，随儿童年龄的增加，可适当增至一次2片。
本发明蒙脱石分散片具有剂量易于掌握，运输携带方便，口味适宜便于口服，片面光滑，色泽一致。
具体实施方式
以下通过实施例和实验例对本发明做进一步说明，但并不受限于此。
实施例1
蒙脱石1000g；微晶纤维素100g；羧甲基淀粉钠30g；糖精酸钠2.34g；香草醛1.34g；阿斯巴甜1.0g
制备工艺：先将糖精酸钠，阿斯巴甜，香草醛混合均匀后，用等容积递增法与微晶纤维素，蒙脱石和羧甲基淀粉钠10g混匀，制粒，干燥，整粒，再加入羧甲基淀粉钠20g混匀，压制成1000片即得。
实施例2
蒙脱石1000g；微晶纤维素200g；羧甲基淀粉钠21g；阿斯巴甜5.0g
制备工艺：将阿斯巴甜用等容积递增法与微晶纤维素，蒙脱石和羧甲基淀粉钠7g混匀，制粒，干燥，整粒，再加入羧甲基淀粉钠14g混匀，压制成1000片即得。
实施例3
蒙脱石1000g；微晶纤维素50g；羧甲基淀粉钠50g；糖精酸钠2.34g；阿斯巴甜1.0g。
制备工艺：先将糖精酸钠，蛋白糖混合均匀后，用等容积递增法与微晶纤维素，蒙脱石和羧甲基淀粉钠10g混匀，制粒，干燥，整粒，再加入羧甲基淀粉钠40g混匀，压制成1000片即得。
实施例4
蒙脱石1000g；羧甲基淀粉100g；羧甲基淀粉钠10g；低取代羟丙基纤维素20g；香草醛1.34g；阿斯巴甜3.0g。
制备工艺：先将蛋白糖，香草醛混合均匀后，用等容积递增法与微晶纤维素，蒙脱石和羧甲基淀粉钠10g混匀，制粒，干燥，整粒，再加入低取代羟丙基纤维素20g混匀，压制成1000片即得。
实施例5
蒙脱石1000g；微晶纤维素100g；羧甲基淀粉钠30g；糖精酸钠2.34g；香草醛1.34g；阿斯巴甜1.0g。
制备工艺：先将糖精酸钠，蛋白糖，香草醛混合均匀后，用等容积递增法与微晶纤维素，蒙脱石和30g羧甲基淀粉钠混匀，制粒，干燥，整粒，压制成1000片即得。
实施例6
蒙脱石1000g；微晶纤维素100g；交联羧甲基纤维素钠10g；20g；糖精酸钠2g；香草醛1g；阿斯巴甜1.0g。
制备工艺：先将糖精酸钠，蛋白糖，香草醛混合均匀后，用等容积递增法与微晶纤维素，蒙脱石和交联羧甲基纤维素钠10g混匀，制粒，干燥，整粒，再加入20g交联羧甲基纤维素钠混匀，压制成1000片即得。
实施例7
蒙脱石1000g；微晶纤维素100g；交联羧甲基纤维素钠30g；糖精酸钠2.34g；香草醛1.34g；阿斯巴甜1.0g；
制备工艺：先将糖精酸钠，蛋白糖，香草醛混合均匀后，用等容积递增法与微晶纤维素，蒙脱石和交联羧甲基纤维素钠10g混匀，制粒，干燥，整粒，再加入交联羧甲基纤维素钠20g混匀，压制成2000片即得。
实验例1
本发明蒙脱石分散片分散均匀性实验。
样品：蒙脱石分散片(按本发明实施例1制备，批号为：020901、020902、020903)
实验方法：分别取不同区号蒙脱石分散片各两片，置于100ml的20℃±1℃水中，然后过2号筛。
实验结果：020901、020902、020903三批蒙脱石分散片分别于45秒，50秒，55秒崩解，并全部通过2号筛。
Claims (12)
1、一种蒙脱石分散片，其特征在于由蒙脱石、填充剂和崩解剂组成。
2、根据权利要求1所述分散片，其特征在于由100重量份蒙脱石，3-20重量份填充剂和1-8重量份崩解剂组成。
3、根据权利要求2所述分散片，其特征在于由100重量份蒙脱石，10重量份填充剂和3重量份崩解剂组成。
4、根据权利要求1-3任一所述分散片，其特征在于崩解剂为羧甲基淀粉钠、低取代羟丙基纤维素和交联羧甲基纤维素钠中的一种、两种或两种以上组合。
5、根据权利要求1-3任一所述分散片，其特征在于上述崩解剂为内加崩解剂和外加崩解剂，其中内加崩解剂和外加崩解剂为羧甲基淀粉钠、低取代羟丙基纤维素和交联羧甲基纤维素钠中的一种、两种或两种以上组合。
6、根据权利要求5所述分散片，其特征在于内加崩解剂和外加崩解剂的重量比为1∶1-4。
7、根据权利要求6所述分散片，其特征在于内加崩解剂和外加崩解剂的重量比为1∶2。
8、根据权利要求1-3任一所述分散片，其特征在于填充剂为微晶纤维素、羧甲基淀粉和淀粉中的一种、两种或两种以上组合。
9、根据权利要求1-3任一所述分散片，其特征在于还由矫味剂组成。
10、根据权利要求9所述的分散片，其特征在于矫味剂为甜菊糖、糖精钠、阿斯巴甜、香草醛和乙基香草醛中的一种、两种或两种以上组合。
11、根据权利要求1-3任一所述分散片，其特征在于含蒙脱石应为标示量的80.0％-95.0％；在鉴别项下：应显硅酸盐，铝盐的阳性反应；在检查项下：每片应吸附硫酸士的宁(C42H44NO4·H2SO4·5H2O)0.3～0.5g，含二氧化硅不得少于500mg，三氧化二铝不得少于100mg，其溶出度应为片重的70％以上。
12、权利要求1-3任一所述分散片的制备工艺为：将矫味剂均匀后，用等容积递增法与填充剂、蒙脱石和内加崩解剂混均，制粒，再加入外加崩解剂混匀，压制成片即得。
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200410042539XA CN100340235C (zh) | 2004-05-21 | 2004-05-21 | 蒙脱石分散片及其制备工艺 |
| PCT/CN2005/000715 WO2005112881A1 (en) | 2004-05-21 | 2005-05-23 | The dispersible montmorillonite tablet and its preparation technology |
| KR1020067026629A KR101222373B1 (ko) | 2004-05-21 | 2005-05-23 | 녹점토 분산성 정제 및 그 제조 |
| ES05752400T ES2426994T3 (es) | 2004-05-21 | 2005-05-23 | Comprimido de montmorillonita dispersable y su tecnología de preparación |
| EP05752400.1A EP1747775B1 (en) | 2004-05-21 | 2005-05-23 | The dispersible montmorillonite tablet and its preparation technology |
| US11/597,219 US8337889B2 (en) | 2004-05-21 | 2005-05-23 | Smectite dispersible tablets and the preparation thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200410042539XA CN100340235C (zh) | 2004-05-21 | 2004-05-21 | 蒙脱石分散片及其制备工艺 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1698648A true CN1698648A (zh) | 2005-11-23 |
| CN100340235C CN100340235C (zh) | 2007-10-03 |
Family
ID=35428233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB200410042539XA Expired - Lifetime CN100340235C (zh) | 2004-05-21 | 2004-05-21 | 蒙脱石分散片及其制备工艺 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8337889B2 (zh) |
| EP (1) | EP1747775B1 (zh) |
| KR (1) | KR101222373B1 (zh) |
| CN (1) | CN100340235C (zh) |
| ES (1) | ES2426994T3 (zh) |
| WO (1) | WO2005112881A1 (zh) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1927220B (zh) * | 2006-08-24 | 2010-05-12 | 广东邦民制药厂有限公司 | 一种用于治疗腹泻及胃炎的蒙脱石凝胶制剂及其制备方法 |
| CN104055793A (zh) * | 2014-06-09 | 2014-09-24 | 山东司邦得制药有限公司 | 一种铁基蒙脱石分散片及其制备方法 |
| CN104173371A (zh) * | 2007-08-13 | 2014-12-03 | 益普生制药股份有限公司 | 粘土基的矫味治疗组合物 |
| CN105055355A (zh) * | 2015-09-14 | 2015-11-18 | 山东司邦得制药有限公司 | 羟基铝蒙脱石咀嚼片及其制备方法和应用 |
| CN105902625A (zh) * | 2016-05-26 | 2016-08-31 | 朱胜利 | 一种小儿止泻药的服用方法 |
| CN107648184A (zh) * | 2017-11-23 | 2018-02-02 | 铜陵市东方矿冶机械有限责任公司 | 硫酸阿托品倍散及其制备方法 |
| CN110974845A (zh) * | 2019-12-25 | 2020-04-10 | 苏州华健瑞达医药技术有限公司 | 改善胃肠道健康的药物组合物及其制备方法、药物制剂的制备方法 |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1912520B1 (en) | 2005-07-19 | 2020-01-22 | Texas Enterosorbents Inc. | Preservative and additive for food and feed |
| AU2007277428B2 (en) | 2006-06-27 | 2013-09-19 | The Texas A & M University System | Composition for the enterosorption and management of toxins comprising a calcium aluminosilicate clay |
| ES2732280T3 (es) * | 2006-06-27 | 2019-11-21 | Texas Enterosorbents Inc | Producto farmacéutico de aluminosilicato de calcio |
| FR2912059B1 (fr) * | 2007-02-06 | 2013-04-05 | Scras | Utilisation d'argiles pour le traitement de la maladie coeliaque |
| GB0708929D0 (en) * | 2007-05-09 | 2007-06-20 | Glaxosmithkline Consumer Healt | Composition |
| US20130101642A1 (en) * | 2011-10-20 | 2013-04-25 | Texas Enterosorbents Inc. | Methods and compositions for treating oral mucositis |
| US8956664B2 (en) | 2011-10-20 | 2015-02-17 | Salient Pharmaceuticals Incorporated | Methods and compositions for treating mucositis |
| DE102012207471A1 (de) * | 2012-05-04 | 2013-11-07 | Fim Biotech Gmbh | Mineralische Verbindung und deren Modifikationen zur Anwendung bei chronisch-entzündlichen Darmerkrankungen |
| DE102012014848A1 (de) * | 2012-07-27 | 2012-10-31 | Heilerde-Gesellschaft Luvos Just GmbH & Co. KG | Heilerde-Zubereitung |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK282071B6 (sk) * | 1991-01-30 | 2001-10-08 | The Wellcome Foundation Limited | Tableta dispergovateľná vo vode a spôsob jej prípravy |
| RU2125460C1 (ru) * | 1997-11-17 | 1999-01-27 | Закрытое акционерное общество научно-производственная фирма "Новь" | Биостимулирующее средство |
| US6916495B2 (en) * | 1999-02-24 | 2005-07-12 | Allan Taylor | Preparation for regulating lower bowel function |
| GB9918020D0 (en) | 1999-07-30 | 1999-09-29 | Unilever Plc | Detergent compositions |
| CN1298707A (zh) * | 1999-12-08 | 2001-06-13 | 翟永功 | 新矿物药材蒙脱石 |
| US6399591B1 (en) * | 2000-01-19 | 2002-06-04 | Yung-Shin Pharmaceutical Ind. Co., Ltd. | Chargeable pharmaceutical tablets |
| CN1326746A (zh) | 2000-06-01 | 2001-12-19 | 翟永功 | 蒙脱石做为兽药和饲料添加剂成分 |
| EP1201742A1 (en) * | 2000-10-31 | 2002-05-02 | The Procter & Gamble Company | Detergent compositions |
| WO2003018477A1 (en) * | 2001-08-24 | 2003-03-06 | Southern Clay Products, Inc. | Methods for making synthetic smectites |
| AU2007203715B2 (en) * | 2006-01-05 | 2012-08-02 | Veloxis Pharmaceuticals A/S | Disintegrating loadable tablets |
-
2004
- 2004-05-21 CN CNB200410042539XA patent/CN100340235C/zh not_active Expired - Lifetime
-
2005
- 2005-05-23 WO PCT/CN2005/000715 patent/WO2005112881A1/zh active Application Filing
- 2005-05-23 KR KR1020067026629A patent/KR101222373B1/ko active IP Right Grant
- 2005-05-23 ES ES05752400T patent/ES2426994T3/es active Active
- 2005-05-23 US US11/597,219 patent/US8337889B2/en not_active Expired - Fee Related
- 2005-05-23 EP EP05752400.1A patent/EP1747775B1/en not_active Not-in-force
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1927220B (zh) * | 2006-08-24 | 2010-05-12 | 广东邦民制药厂有限公司 | 一种用于治疗腹泻及胃炎的蒙脱石凝胶制剂及其制备方法 |
| CN104173371A (zh) * | 2007-08-13 | 2014-12-03 | 益普生制药股份有限公司 | 粘土基的矫味治疗组合物 |
| CN104055793A (zh) * | 2014-06-09 | 2014-09-24 | 山东司邦得制药有限公司 | 一种铁基蒙脱石分散片及其制备方法 |
| CN105055355A (zh) * | 2015-09-14 | 2015-11-18 | 山东司邦得制药有限公司 | 羟基铝蒙脱石咀嚼片及其制备方法和应用 |
| CN105055355B (zh) * | 2015-09-14 | 2018-08-28 | 山东司邦得制药有限公司 | 羟基铝蒙脱石咀嚼片及其制备方法和应用 |
| CN105902625A (zh) * | 2016-05-26 | 2016-08-31 | 朱胜利 | 一种小儿止泻药的服用方法 |
| CN107648184A (zh) * | 2017-11-23 | 2018-02-02 | 铜陵市东方矿冶机械有限责任公司 | 硫酸阿托品倍散及其制备方法 |
| CN110974845A (zh) * | 2019-12-25 | 2020-04-10 | 苏州华健瑞达医药技术有限公司 | 改善胃肠道健康的药物组合物及其制备方法、药物制剂的制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005112881A1 (en) | 2005-12-01 |
| EP1747775A1 (en) | 2007-01-31 |
| US8337889B2 (en) | 2012-12-25 |
| WO2005112881A8 (en) | 2007-02-22 |
| KR20070020512A (ko) | 2007-02-21 |
| CN100340235C (zh) | 2007-10-03 |
| EP1747775A4 (en) | 2008-05-21 |
| US20080038337A1 (en) | 2008-02-14 |
| ES2426994T3 (es) | 2013-10-28 |
| KR101222373B1 (ko) | 2013-01-15 |
| EP1747775B1 (en) | 2013-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100340235C (zh) | 蒙脱石分散片及其制备工艺 | |
| CN105943554A (zh) | 含有镧化合物的胶囊和粉末制剂 | |
| CN1850087A (zh) | 一种含有头孢克肟的泡腾片及制法 | |
| CN1555794A (zh) | 奥拉西坦分散片及其制备方法 | |
| CN102286045B (zh) | 罗红霉素一水合物结晶、其制备方法及含该结晶和盐酸氨溴索组合的组合物干混悬剂 | |
| CN101461788A (zh) | 一种间苯三酚口腔崩解片及其制备方法 | |
| CN106822097B (zh) | 一种用于减肥的含奥利司他的药物组合物 | |
| CN1287792C (zh) | 孟鲁司特钠的分散片剂型 | |
| CN115089618B (zh) | 一种用于防治骨质疏松的药物组合物及其制备方法 | |
| CN1958010A (zh) | 一种中药复方制剂及其制备方法 | |
| CN1319533C (zh) | 盐酸头孢他美酯分散片及其制备方法 | |
| CN105106127A (zh) | 一种蒙脱石微丸干混悬剂及其制备方法 | |
| CN1443535A (zh) | 马来酸替加色罗口服制剂及其制备工艺——治疗肠易惹综合征 | |
| CN1172433A (zh) | 胃溃宁制剂 | |
| CN1228076C (zh) | 治血热引起月经先期伴量多的中药 | |
| CN104161746A (zh) | 无糖型赖氨葡锌颗粒组合物和制法 | |
| CN1915324A (zh) | 小儿扶脾制剂及其制备方法 | |
| CN100335064C (zh) | 一种葛根黄酮微丸制剂及其制备方法 | |
| CN1414847A (zh) | 含吡喹酮的缓释抗蠕虫组合物 | |
| CN1634061A (zh) | 双酚伪麻药物制剂及其制备方法 | |
| CN1528273A (zh) | 一种镇痛药盐酸曲马多口腔崩解片及其制备方法 | |
| CN1903869A (zh) | 替比夫定的衍生物盐及其制备方法和药物应用 | |
| CN1931140A (zh) | 氢溴酸加兰他敏口崩片及其制备方法 | |
| CN1732911A (zh) | 琥珀酸亚铁缓释制剂及其制备方法 | |
| CN114832020B (zh) | 一种用于防治儿童发育障碍的药物组合物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20100309 Address after: 264003 Laishan, Shandong Province Bao Road, No. 9 District, No. Patentee after: SHANDONG LUYE PHARMACEUTICAL Co.,Ltd. Patentee after: YANTAI LUYE ANIMAL HEALTH PRODUCTS Co.,Ltd. Address before: 264003 Laishan, Shandong Province Bao Road, No. 9 District, No. Patentee before: SHANDONG LUYE PHARMACEUTICAL Co.,Ltd. |
|
| CX01 | Expiry of patent term |
Granted publication date: 20071003 |